130 related articles for article (PubMed ID: 36439951)
1. A Variable-Clustering-Based Feature Selection to Improve Positive and Negative Discrimination of P53 Protein in Colorectal Cancer Patients.
Wang L; Feng L; Wang J; Li J; Li H; Zeng F; Sun L
Comput Math Methods Med; 2022; 2022():9261713. PubMed ID: 36439951
[TBL] [Abstract][Full Text] [Related]
2. Gene Selection for the Discrimination of Colorectal Cancer.
Wang W; Xie G; Ren Z; Xie T; Li J
Curr Mol Med; 2020; 20(6):415-428. PubMed ID: 31746296
[TBL] [Abstract][Full Text] [Related]
3. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
[TBL] [Abstract][Full Text] [Related]
4. Critical Role of p53 and K-ras in the Diagnosis of Early Colorectal Cancer: a One-year, Single-center Analysis.
Lu HY; Lin RT; Zhou GX; Yu TM; Liu ZJ
Int J Med Sci; 2017; 14(11):1154-1162. PubMed ID: 29104470
[No Abstract] [Full Text] [Related]
5. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of p53 positive in colorectal cancer: A retrospective cohort study.
Wang P; Liang J; Wang Z; Hou H; Shi L; Zhou Z
Tumour Biol; 2017 May; 39(5):1010428317703651. PubMed ID: 28468582
[TBL] [Abstract][Full Text] [Related]
7. Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.
De Oliveira LP; López I; Dos Santos EM; Tucci P; Marín M; Soares FA; Rossi BM; Coudry Rde A
Oncol Rep; 2014 Mar; 31(3):1396-406. PubMed ID: 24366026
[TBL] [Abstract][Full Text] [Related]
8. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52.
Zhou Q; Hou Z; Zuo S; Zhou X; Feng Y; Sun Y; Yuan X
Cancer Sci; 2019 Apr; 110(4):1194-1207. PubMed ID: 30690837
[TBL] [Abstract][Full Text] [Related]
9. The p53-inducible CLDN7 regulates colorectal tumorigenesis and has prognostic significance.
Hou Y; Hou L; Liang Y; Zhang Q; Hong X; Wang Y; Huang X; Zhong T; Pang W; Xu C; Zhu L; Li L; Fang J; Meng X
Neoplasia; 2020 Nov; 22(11):590-603. PubMed ID: 32992138
[TBL] [Abstract][Full Text] [Related]
10. Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer.
Nasif WA; Lotfy M; El-Sayed IH; El-Kenawy Ael-M; El-Shahat M; El-Hak NG
Med Oncol; 2006; 23(2):237-44. PubMed ID: 16720924
[TBL] [Abstract][Full Text] [Related]
11. FOXD3, frequently methylated in colorectal cancer, acts as a tumor suppressor and induces tumor cell apoptosis under ER stress via p53.
Xu M; Zhu J; Liu S; Wang C; Shi Q; Kuang Y; Fang X; Hu X
Carcinogenesis; 2020 Sep; 41(9):1253-1262. PubMed ID: 31784734
[TBL] [Abstract][Full Text] [Related]
12. Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis.
Rokavec M; Bouznad N; Hermeking H
Cell Mol Gastroenterol Hepatol; 2019; 7(4):783-802. PubMed ID: 30831320
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profile of peripheral blood in colorectal cancer.
Chang YT; Huang CS; Yao CT; Su SL; Terng HJ; Chou HL; Chou YC; Chen KH; Shih YW; Lu CY; Lai CH; Jian CE; Lin CH; Chen CT; Wu YS; Lin KS; Wetter T; Chang CW; Chu CM
World J Gastroenterol; 2014 Oct; 20(39):14463-71. PubMed ID: 25339833
[TBL] [Abstract][Full Text] [Related]
14. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
Li XL; Zhou J; Chen ZR; Chng WJ
World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
[TBL] [Abstract][Full Text] [Related]
15. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.
Zhu ZZ; Liu B; Wang AZ; Jia HR; Jin XX; He XL; Hou LF; Zhu GS
J Zhejiang Univ Sci B; 2008 Nov; 9(11):847-52. PubMed ID: 18988302
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
19. Choline-induced SLC5A7 impairs colorectal cancer growth by stabilizing p53 protein.
Yin Y; Jiang Z; Fu J; Li Y; Fang C; Yin X; Chen Y; Chen N; Li J; Ji Y; Su X; Qiu M; Huang W; Zhang B; Deng H; Dai L
Cancer Lett; 2022 Jan; 525():55-66. PubMed ID: 34562520
[TBL] [Abstract][Full Text] [Related]
20. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
